{"id":"W2048348290","doi":"10.3389/fonc.2014.00233","title":"Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future","year":2014,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Anaplastic lymphoma kinase; Medicine; Clinical trial; Targeted therapy; Epidermal growth factor receptor; Lung cancer; EGFR inhibitors; Crizotinib; Biomarker; Oncology; Pharmacology; Cancer; Internal medicine; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006395615,0.0003460361,0.003118423,0.0004042938,0.00006673508,0.00002365324,0.0001113503,0.0003265667,0.00003474892],"category_scores_gemma":[0.00009789097,0.0002429933,0.0001519613,0.0002903543,0.0000729172,0.00003737441,0.0000682202,0.0002571715,0.000006759448],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005840001,"about_ca_system_score_gemma":0.0003472801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003520386,"about_ca_topic_score_gemma":0.00007474071,"domain_scores_codex":[0.9977897,0.000556959,0.0006647873,0.0005384787,0.0001400322,0.0003100639],"domain_scores_gemma":[0.9987898,0.0003241988,0.0002537186,0.0003232631,0.00005066311,0.0002583979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001415277,0.00005086252,0.0001706582,0.001677755,0.0004441977,0.00003142553,0.001151241,1.090135e-7,2.522194e-7,0.00004628545,0.359164,0.6371217],"study_design_scores_gemma":[0.001713933,0.0002829405,0.0003046454,0.001702254,0.001251442,0.00001761808,0.000293237,4.239064e-7,2.984081e-7,0.0001624114,0.9940639,0.0002069334],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002599589,0.9790564,0.0002661065,0.01343883,0.001901099,0.002872156,0.0000959851,0.00002740346,0.002316],"genre_scores_gemma":[0.000005309731,0.970392,0.0166785,0.0009839124,0.00227509,0.0006852541,0.000101388,0.00004678476,0.00883179],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6369148,"threshold_uncertainty_score":0.990898,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02839061432387186,"score_gpt":0.4102419312717828,"score_spread":0.381851316947911,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}